IN2014MN01937A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01937A IN2014MN01937A IN1937MUN2014A IN2014MN01937A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A IN 1937MUN2014 A IN1937MUN2014 A IN 1937MUN2014A IN 2014MN01937 A IN2014MN01937 A IN 2014MN01937A
- Authority
- IN
- India
- Prior art keywords
- subject
- metabolic syndrome
- diabetes mellitus
- risk
- level
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608350P | 2012-03-08 | 2012-03-08 | |
| EP12158680 | 2012-03-08 | ||
| EP12165062 | 2012-04-20 | ||
| PCT/EP2013/054801 WO2013132090A1 (en) | 2012-03-08 | 2013-03-08 | A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01937A true IN2014MN01937A (enrdf_load_stackoverflow) | 2015-07-10 |
Family
ID=49115970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1937MUN2014 IN2014MN01937A (enrdf_load_stackoverflow) | 2012-03-08 | 2013-03-08 |
Country Status (9)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103308689B (zh) * | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| EP3002589A1 (en) * | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| US10900978B2 (en) | 2015-02-27 | 2021-01-26 | Sphingotec Gmbh | Method for predicting the risk of obesity in a subject |
| US10473670B2 (en) | 2016-02-25 | 2019-11-12 | University Of Kentucky Research Foundation | Method of predicting obesity comprising measuring neurotensin |
| WO2022203533A1 (ru) * | 2021-03-25 | 2022-09-29 | Владимир Валерьевич ВОЛОБУЕВ | Способ оценки предрасположенности к различным формам сахарного диабета 2го типа |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8709871D0 (en) * | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5430047A (en) * | 1994-04-07 | 1995-07-04 | Warner-Lambert Company | Neurotensin antagonists |
| EP0803255A4 (en) * | 1994-06-03 | 1999-06-30 | Tsumura & Co | MEDICINAL COMPOSITION |
| AU757658B2 (en) * | 1998-03-09 | 2003-02-27 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6248527B1 (en) * | 1998-10-21 | 2001-06-19 | Millennium Pharmaceuticals, Inc. | Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| WO2003000712A1 (fr) * | 2001-06-20 | 2003-01-03 | Kissei Pharmaceutical Co., Ltd. | Derive heterocyclique azote, composition medicinale contenant ce derive, leur utilisation medicinale et intermediaire associe |
| EP1427750B1 (en) | 2001-08-30 | 2010-12-08 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| PT1531791E (pt) | 2002-06-07 | 2010-12-16 | Dyax Corp | Prevenção e redução da isquémia |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| CA2580881A1 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag | Use of microproteins as tryptase inhibitors |
| DE102005003687A1 (de) * | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
| CN101166981A (zh) * | 2005-04-11 | 2008-04-23 | 阿斯利康(瑞典)有限公司 | 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒 |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| JP5954990B2 (ja) | 2008-11-03 | 2016-07-20 | モレキュラー・パートナーズ・アーゲーＭｏｌｅｃｕｌａｒ Ｐａｒｔｎｅｒｓ Ａｇ | Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質 |
| EP2370471B1 (en) * | 2008-12-05 | 2017-02-22 | Angiochem Inc. | Neurotensin conjugate and uses thereof |
| US8586043B2 (en) | 2009-01-07 | 2013-11-19 | Inserm ( Institut National De La Sante Et De La Recherche Medicale) | Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1 |
| RU2550272C2 (ru) | 2009-08-27 | 2015-05-10 | Коваген Аг | Новые il-17-связывающие соединения и их медицинское применение |
| EP2494364A1 (en) * | 2009-10-29 | 2012-09-05 | Tethys Bioscience, Inc. | Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes |
| ES2441803T3 (es) | 2009-12-14 | 2014-02-06 | Scil Proteins Gmbh | Un método para identificar proteínas de ubicuitina heteromultímeras modificadas con capacidad para unirse a ligandos |
| UA58612U (uk) * | 2010-06-04 | 2011-04-26 | Высшее Государственное Учебное Заведение «Украинская Медицинская Стоматологическая Академия» | Спосіб діагностики інсулінорезистентності у хворих на метаболічний синдром та цукровий діабет 2 типу |
| AU2011263786B2 (en) | 2010-06-08 | 2014-11-13 | Astrazeneca Ab | Tear lipocalin muteins binding IL-4 R alpha |
| US10900978B2 (en) * | 2015-02-27 | 2021-01-26 | Sphingotec Gmbh | Method for predicting the risk of obesity in a subject |
-
2012
- 2012-10-08 CN CN201210509621.3A patent/CN103308670B/zh active Active
-
2013
- 2013-03-08 IN IN1937MUN2014 patent/IN2014MN01937A/en unknown
- 2013-03-08 RU RU2014140427A patent/RU2685713C2/ru active
- 2013-03-08 JP JP2014560405A patent/JP6262669B2/ja active Active
- 2013-03-08 EP EP13708803.5A patent/EP2823316B1/en active Active
- 2013-03-08 WO PCT/EP2013/054801 patent/WO2013132090A1/en active Application Filing
- 2013-03-08 TR TR2018/11201T patent/TR201811201T4/tr unknown
- 2013-03-08 US US14/383,422 patent/US10520512B2/en active Active
- 2013-03-08 ES ES13708803.5T patent/ES2684512T3/es active Active
-
2019
- 2019-12-18 US US16/719,507 patent/US20200326350A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10520512B2 (en) | 2019-12-31 |
| US20200326350A1 (en) | 2020-10-15 |
| CN103308670A (zh) | 2013-09-18 |
| TR201811201T4 (tr) | 2018-09-21 |
| RU2685713C2 (ru) | 2019-04-23 |
| ES2684512T3 (es) | 2018-10-03 |
| EP2823316B1 (en) | 2018-05-23 |
| EP2823316A1 (en) | 2015-01-14 |
| JP2015512048A (ja) | 2015-04-23 |
| JP6262669B2 (ja) | 2018-01-17 |
| CN103308670B (zh) | 2017-06-09 |
| WO2013132090A1 (en) | 2013-09-12 |
| RU2014140427A (ru) | 2016-04-27 |
| US20150056203A1 (en) | 2015-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013159872A8 (en) | Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope | |
| IN2014MN01937A (enrdf_load_stackoverflow) | ||
| NZ630421A (en) | Biomarkers predictive for clinical response for glatiramer acetate | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| EP2596132A4 (en) | METHODS OF DETECTING SIGNATURES OF DISEASES OR PATHOLOGIES IN BIOLOGICAL LIQUIDS | |
| NZ601590A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| BR112013000760A2 (pt) | método e aparelho para medir a espessura do tecido adiposo | |
| WO2013067495A3 (en) | Personal spirometer | |
| BR112015003046A2 (pt) | sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador. | |
| WO2010041046A8 (en) | Granin proteins as markers of heart disease | |
| MX2015012304A (es) | Metodo no invasivo para la medicion de metabolitos para la salud de la piel. | |
| WO2016044338A3 (en) | Methods and systems for diagnosing sleep disorders | |
| WO2014004889A3 (en) | Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm | |
| WO2014078468A3 (en) | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent | |
| MX381530B (es) | Método in vitro para el diagnóstico de la enfermedad de niemann-pick. | |
| IN2014MN01940A (enrdf_load_stackoverflow) | ||
| BR112015014232A2 (pt) | lesão renal aguda | |
| WO2011085057A3 (en) | Methods for detecting insulin autoantibody | |
| WO2015192854A3 (en) | Methods and tools for predicting steatohepatitis | |
| WO2013132089A3 (en) | A method for predicting the risk of getting cancer or diagnosing cancer in a female subject | |
| WO2016066862A3 (en) | A method for predicting the risk of obesity in a subject | |
| WO2015010042A3 (en) | Method of determination of risk of 2 hour blood glucose equal to or greater than 140 mg/di | |
| WO2013101276A3 (en) | Diagnosis and detection of disease conditions modulated by activation of the sphingolipid pathway | |
| GB201114909D0 (en) | Biomarkers for lysosomal storage disorders | |
| BR112014010529A2 (pt) | agente, métodos para tratar hipertensão pulmonar, e, método de diagnóstico ou de prognóstico para a determinação se um paciente teve ou tem uma predisposição à hipertensão pulmonar |